Shares of U.S. Bioscience Inc. posted a second day of large gainsWednesday, rising $9.63 to close at $56.75, following Tuesday'sannouncement that the Food and Drug Administration willreview the company's Ethyol product to protect normal cellsfrom chemotherapy. The shares jumped $7.50 on Tuesday.

The Ethyol announcement, coupled with news that U.S.Bioscience granted Schering-Plough Corp. marketing rights tofive products, prompted analysts to raise earnings estimatesfor U.S. Bioscience.

David Webber of Alex. Brown & Sons, who reiterated a "strongbuy" on the stock (AMEX:UBS), projects U.S. approval of Ethyolin the third quarter of 1992. Webber revised his 1992 earningsestimate to 45 cents per share from a loss of 50 cents. Webbersaid his six to 12 month stock price target is $100 per share.

Kidder, Peabody analyst Robert Kupor upgraded his rating onthe West Conshohocken, Pa., company to "buy" from "hold" andraised his 1992 earnings per share estimate to 1 cent from aloss of 56 cents.

Kupor said, however, that he expects a narrow indication forEthyol, which he said could be approved as early as spring1992. He predicted that Ethyol's commercial value will besubstantially less than other analysts' projections. -- KB

(c) 1997 American Health Consultants. All rights reserved.